Literature DB >> 28990272

Impact of bladder cancer on health-related quality of life.

Angela B Smith1,2, Byron Jaeger3, Laura C Pinheiro4, Lloyd J Edwards3, Hung-Jui Tan1,2, Matthew E Nielsen1,2,5, Bryce B Reeve2,4.   

Abstract

OBJECTIVES: To identify changes in health-related quality of life (HRQoL) after diagnosis of bladder cancer in older adults in comparison with a group of adults without bladder cancer (controls). PATIENTS AND METHODS: Data from the Surveillance, Epidemiology and End Results registries were linked with Medicare Health Outcomes Survey (MHOS) data. Medicare beneficiaries aged ≥65 years in the period 1998-2013, who were diagnosed with bladder cancer between baseline and follow-up through the MHOS, were matched with control subjects without cancer using propensity scores. Linear mixed models were used to estimate predictors of HRQoL changes.
RESULTS: After matching, 535 patients with bladder cancer (458 non-muscle-invasive bladder cancer [NMIBC] and 77 with muscle-invasive bladder cancer [MIBC]) and 2 770 control subjects without cancer were identified. Both patients with NMIBC and those with MIBC reported significant declines in HRQoL scores over time vs controls: physical component summary -2 and -5.3 vs -0.4, respectively; bodily pain -1.9 and -3.6 vs -0.7; role physical -2.7 and -4.7 vs -0.7; general health -2.4 and -6.1 vs 0; vitality -1.2 and -3.5 vs -0.1; and social functioning -2.1 and -5.7 vs -0.8. All scores ranged from 0 to 100. When stratified by time since diagnosis, HRQoL improved over 1 year for some domains (role physical), but remained lower across most domains.
CONCLUSIONS: After diagnosis, patients with bladder cancer experienced significant declines in physical, mental and social HRQoL relative to controls. Decrements were most pronounced among individuals with MIBC. Methods to better understand and address HRQoL decrements among patients with bladder cancer are needed.
© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #BCSM; #BladderCancer; health-related quality of life; patient-reported outcomes; treatment outcome; urinary bladder neoplasms; urological surgery

Mesh:

Year:  2017        PMID: 28990272     DOI: 10.1111/bju.14047

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  37 in total

1.  Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Authors:  Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2019-01-31       Impact factor: 1.862

Review 2.  Bladder Cancer Survivorship.

Authors:  Sumeet K Bhanvadia
Journal:  Curr Urol Rep       Date:  2018-11-09       Impact factor: 3.092

3.  Survival outcomes of non-definitive therapy for muscle-invasive bladder cancer.

Authors:  Kiyoaki Nishihara; Kosuke Ueda; Hirofumi Kurose; Naoyuki Ogasawara; Tasuku Hiroshige; Katsuaki Chikui; Kazuhisa Ejima; Keiichiro Uemura; Makoto Nakiri; Shigetaka Suekane; Tsukasa Igawa
Journal:  Oncol Lett       Date:  2022-02-17       Impact factor: 2.967

4.  SMARCC1 Enters the Nucleus via KPNA2 and Plays an Oncogenic Role in Bladder Cancer.

Authors:  Zhengmao Wei; Jinming Xu; Weiqing Li; Longhua Ou; Yingchen Zhou; Yan Wang; Bentao Shi
Journal:  Front Mol Biosci       Date:  2022-05-20

5.  Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.

Authors:  Bradley McGregor; Peter H O'Donnell; Arjun Balar; Daniel Petrylak; Jonathan Rosenberg; Evan Y Yu; David I Quinn; Elisabeth I Heath; Mary Campbell; Zsolt Hepp; Caroline McKay; Joyce Steinberg; Antoine Regnault; Flora Mazerolle; Matthew D Galsky
Journal:  Eur Urol       Date:  2022-02-12       Impact factor: 24.267

6.  Assessment of Pain, Acceptance of Illness, Adaptation to Life, and Strategies of Coping With the Disease, in Patients With Bladder Cancer.

Authors:  Urszula Religioni; Aleksandra Czerw; Andrzej Deptala
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

7.  Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review.

Authors:  Claudia Rutherford; Manish I Patel; Margaret-Ann Tait; David P Smith; Daniel S J Costa; Shomik Sengupta; Madeleine T King
Journal:  Qual Life Res       Date:  2020-09-22       Impact factor: 4.147

8.  Quality of life and functional outcomes after radical cystectomy with ileal orthotopic neobladder replacement for bladder cancer: a multicentre observational study.

Authors:  E Pons-Tostivint; M Roumiguié; V Tostivint; G Verhoest; B Cabarrou; J Gas; P Coloby; J Zgheib; M Thoulouzan; M Soulié; X Gamé; J B Beauval
Journal:  World J Urol       Date:  2020-10-16       Impact factor: 4.226

9.  How to assess and improve health-related quality of life in bladder cancer patients.

Authors:  Francesco Soria; Paolo Gontero
Journal:  Transl Androl Urol       Date:  2018-03

10.  Predictive value of β-catenin in bladder cancer: a systematic review and meta-analysis.

Authors:  Jin Ren; Yaodong Yang; Taifang Peng; Dong Xu
Journal:  Biosci Rep       Date:  2020-09-30       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.